Method of predicting responsiveness to autologous adoptive cell transfer therapy
A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8 + CD28 − CD152 − signature in a sample of the subject, wherein a frequency of TILs having the CD8 + CD28 − CD152 − signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.
1. A method of predicting responsiveness to autologous adoptive cell transfer therapy in a subject having metastatic melanoma, the method comprising contacting tumor infiltrating lymphocytes (TILs) of a tumor sample isolated from the subject with an antibody which recognizes CD8, an antibody which recognizes CD28 and an antibody which recognizes CD152 so as to determine a frequency of TILs having a CD8+CD28−CD152− signature, wherein a frequency of TILs having said CD8+CD28-CD152− signature below 25% is predicative of a negative responsiveness to autologous adoptive cell transfer therapy.
2. The method of claim 1 , further comprising analyzing a frequency of TILs having a CD8+CD69+CD33− signature in the tumor sample of the subject, wherein a frequency of TILs having said CD8+CD69+CD33− signature above 60% and a CD8+CD28−CD152− signature above 45% is predicative of a negative responsiveness to autologous adoptive cell transfer therapy.
3. The method of claim 1 , further comprising analyzing a frequency of TILs having a CD94+ signature in the sample, wherein a frequency of TILs having said CD8+CD28−CD152− signature below 25%, whilst having a CD94+ signature above 0.7% is further indicative of a negative responsiveness to adoptive cell transfer therapy.